~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~ ~ Phase 3 data of the Launch-HTN ...
Understanding the various aspects of clinical trials can be overwhelming, and many patients with myeloproliferative neoplasms (MPNs) may be hesitant to join because of common misconceptions. However, ...
STATEN ISLAND, N.Y., April 25, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of ...
Patients with cancer often miss out on the benefits of clinical research either due to a dearth of communication from doctors or a lack of comprehension of their complex nature, according to a speaker ...
TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve ...
BRANFORD, Conn., May 28, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today ...
TEL AVIV, Israel and WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology ...
Orbus Therapeutics, Inc., a private pharmaceutical company, today announced it will present updated results from the Phase 3 STELLAR trial investigating eflornithine at the Society for Neuro-Oncology ...
PARIS, France – October 05, 2025 – 5:00 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on ...
Identifying GP2 specific T cell immune response at baseline prior to treatment with GP2 has potential to predict breast cancer recurrence risk and timing of recurrence A positive baseline immune ...
An announcement from Noxopharm Ltd. ( ($AU:NOX) ) is now available. Noxopharm Limited has released its 2025 AGM Corporate Presentation, ...
Humacyte (HUMA) announced the presentation of positive two-year results from the V007 Phase 3 clinical trial of the acellular tissue engineered ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback